4
Changes in Ownership
Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000087
Chief Executive Officer sold 75,000 shares at an average $91.83 ($6,887,484)
- Chief Executive Officer acquired 75,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Klein Lawrence Otto · Chief Executive Officer
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-09-01 | Exercise or conversion : show line 1 in the form 10b5-1 | +75,000 | $7.80 | $585,000 | 1,000,580 | D |
| 2026-09-01 | Sale : show line 2 in the form 10b5-1 | −6,604 | $90.79 | $599,556 | 993,976 | D |
| 2026-09-01 | Sale : show line 3 in the form 10b5-1 | −63,596 | $91.90 | $5,844,237 | 930,380 | D |
| 2026-09-01 | Sale : show line 4 in the form 10b5-1 | −4,800 | $92.44 | $443,691 | 925,580 | D |
| Open-market sales · 75,000 sh · avg $91.83 · $6,887,484 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-09-01 | Exercise or conversion : show line 5 in the form 10b5-1 Employee Warrant (right to buy) | −75,000 | 1,553,513 | D |
Loading xslF345X06/form4.xml…